SYMQY.US SymBio Pharmaceuticals Limited
- Market cap
- USD 37.3M
- P/E
- -
- P/B
- 2.74x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SYMQY.US undervalued?
Graham numberThe Graham number of SymBio Pharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SymBio Pharmaceuticals Limited fundamental analysis
No fundamental analysis for SymBio Pharmaceuticals Limited yet.
SymBio Pharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Full company profileSymBio Pharmaceuticals Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SymBio Pharmaceuticals Limited annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.37B | 3.44B | 3.84B | 2.84B | 2.99B | 8.25B | 10.0B | 5.59B | 2.45B | 1.37B | 972M |
| Gross Profit | 904M | 1.03B | 1.17B | 865M | 867M | 5.80B | 7.60B | 4.41B | 1.87B | 993M | 709M |
| Operating Income | -2.13B | -3.95B | -2.66B | -4.30B | -4.51B | 1.02B | 1.96B | -812M | -3.88B | -4.66B | -6.57B |
| EBITDA | -2.10B | -3.92B | -2.62B | -4.26B | -4.44B | 1.11B | 2.06B | -716M | -3.78B | -4.82B | -6.57B |
| Net Income | -2.31B | -3.98B | -2.75B | -4.38B | -4.09B | 2.03B | 1.18B | -1.96B | -3.83B | -5.01B | -6.59B |
| EPS | -235 | -319 | -166 | -189 | -124 | 52 | 30 | -49 | -84 | -100 | -78 |
| Balance Sheet | |||||||||||
| Total Assets | 6.88B | 4.25B | 6.24B | 5.27B | 6.27B | 8.45B | 10.4B | 8.17B | 4.97B | 3.87B | 938M |
| Total Liabilities | 1.39B | 1.01B | 1.34B | 874M | 1.62B | 1.71B | 1.93B | 960M | 771M | 2.60B | 2.24B |
| Shareholders' Equity | 5.48B | 3.24B | 4.90B | 4.40B | 4.66B | 6.75B | 8.51B | 7.21B | 4.20B | 1.27B | -1.30B |
| Cash & Short-term Investments | 5.72B | 2.95B | 4.82B | 3.91B | 3.85B | 3.86B | 6.28B | 6.52B | 3.96B | 2.89B | 256M |
| Total Debt | 450M | - | - | - | - | - | - | - | - | 1.98B | 805M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.96B | -3.82B | -2.32B | -4.35B | -4.12B | 140M | 1.61B | -195M | -3.42B | -4.80B | - |
| Capital Expenditure | 27.9M | 57.0M | 39.8M | 217M | 149M | 63.8M | 47.6M | 233M | 46.9M | 525.00 | 0.00 |
| Free Cash Flow | -1.99B | -3.87B | -2.36B | -4.57B | -4.27B | 76.2M | 1.57B | -427M | -3.46B | -4.80B | - |
| Ratios | |||||||||||
| ROE | -42.2% | -122.8% | -56.2% | -99.5% | -87.8% | 30.1% | 13.9% | -27.2% | -91.3% | -393.4% | - |
| ROA | -33.6% | -93.5% | -44.1% | -83.0% | -65.2% | 24.0% | 11.3% | -24.0% | -77.2% | -129.4% | -702.0% |
| Net Profit Margin | -97.7% | -115.5% | -71.8% | -154.2% | -136.9% | 24.6% | 11.8% | -35.1% | -156.3% | -365.3% | -677.2% |
| Debt to Equity | 0.08x | - | - | - | - | - | - | - | - | 1.56x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SymBio Pharmaceuticals Limited dividends
SymBio Pharmaceuticals Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Mar 10, 2022.
Who owns SymBio Pharmaceuticals Limited
Ownership data of SymBio Pharmaceuticals Limited is not available yet.
SymBio Pharmaceuticals Limited company profile
- Company name
- SymBio Pharmaceuticals Limited
- Ticker
- SYMQY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 91
- Fiscal year end
- December
- Address
- Toranomon Towers Office, Minato, Japan, 105-0001
- Phone
- 81 3 5472 1125
- Website
- symbiopharma.com
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
SymBio Pharmaceuticals Limited management
6- Mr. Fuminori YoshidaCEO, President & Representative Director · born 1949
- Yoshiharu TorikaiCorporate Officer
- Masahiko OkunoCorporate Officer
- Hiroyuki HoritaCorporate Officer
- Dr. Minori Rosales M.D., Ph.D.Executive Vice President and Head of Global R&D · born 1963
- Tomonori SetaCorporate Officer